Blue­bird bio dives deep­er in­to its TCR al­liance with Medi­gene, adding $500M in mile­stones and 2 new tar­gets

What­ev­er blue­bird bio $BLUE learned about Medi­gene’s TCR im­munother­a­py tech since it signed up for its ini­tial bil­lion-dol­lar dis­cov­ery pact must have been im­pres­sive. The Cam­bridge, MA-based biotech has jumped back in for a new ex­plo­ration of the in­tra­cel­lu­lar tar­gets that TCR can hit, adding two more projects to the pack­age with an­oth­er $500 mil­lion in mile­stones on the ta­ble.

As with most such pre­clin­i­cal align­ments, the work starts with a small up­front and then grows with the po­ten­tial — or not. Ger­many’s Medi­gene {$MDGEF; ETR: $MDG1} gets $8 mil­lion to start off the ex­pand­ed deal, R&D sup­port to grow its or­ga­ni­za­tion and a $1 mil­lion bonus ear­ly on. And its stock jumped 9% on the news Mon­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.